Company intelligence / Profile preview
Protalix BioTherapeutics
Karmiel, Northern District, Israelprotalix.com ↗
- Ownership
- Public · PLX
- Employees
- ~266
- Development stage
- Commercial
01
Overview
Protalix has commercialized two enzyme replacement therapies for rare diseases—Elelyso®/Uplyso® for Gaucher disease and Elfabrio® for Fabry disease. Elelyso was the first FDA-approved protein produced in a plant cell-based system. Elfabrio received FDA and EMA approval in May 2023. The company’s pipeline includes PRX–115, a PEGylated uricase for uncontrolled gout that completed a first-in-human study with plans to enter Phase II trials, and PRX–119, a long acting DNase I targeting NETs-related diseases[5][6].
- Therapeutic areas
- OncologyRare DiseasesRheumatology
- Modalities
- Recombinant therapeutic proteins (produced in plant cell-based systems)Enzyme replacement therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer Inc. – global rights to taliglucerase alfa except Brazil[5]Chiesi Farmaceutici S.p.A. – global development/commercialization of Elfabrio[5]
04
Financials
- Market cap
- $220M
- Total revenue
- $19.9M
- Enterprise value
- $188.5M
Beyond the preview
Go deeper on Protalix BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protalix BioTherapeutics.